Search "peptides for joint pain" and BPC-157, TB-500 and GHK-Cu come up first, usually as the GLOW blend. None of the three has been tested in a controlled human joint trial. The biggest human trial that actually touches joint pain in this whole library belongs to a compound sold for something else entirely: retatrutide, an investigational GLP-1 class weight-loss drug whose phase 3 knee osteoarthritis trial is the largest, best-designed human study on this page by a wide margin. This guide ranks all five by the strength of the evidence behind them, not by which one is best known for joints.
Summary
| Compound | Best evidence | Stage |
|---|---|---|
| Retatrutide Stocked locally | TRIUMPH-4, a 445-person, 68-week phase 3 trial in people with knee osteoarthritis | Human phase 3 data, but the trial measured weight loss; not an approved or dedicated OA drug |
| BPC-157 Stocked locally | Extensive rat tendon and ligament studies, plus one uncontrolled human knee case series | Mostly animal; the human data is a case series with no control group |
| AOD-9604 | Intra-articular injection in a rabbit osteoarthritis model | Animal only for the joint-specific finding |
| TB-500 Stocked locally | A 2026 rat Achilles tendon study of the short fragment, alongside BPC-157 | Animal only; almost no data specific to the fragment sold as TB-500 |
| GHK-Cu (injectable) Stocked locally | Rat and rabbit wound-collagen studies; no joint-specific study of any kind | Animal and cell work on skin and wounds, not cartilage or joints |
Retatrutide: the largest human trial here, but not a joint-pain drug
Retatrutide activates the GIP, GLP-1 and glucagon receptors and is Eli Lilly's furthest-along triple agonist, not approved anywhere and not registered with FDA Philippines. TRIUMPH-4, reported 11 December 2025, enrolled 445 people with obesity and knee osteoarthritis and ran for 68 weeks, reporting 28.7% mean weight loss and relief of knee pain. That is real phase 3 human data, and it is the only trial on this page run at that scale with that design.
Read it carefully, though. TRIUMPH-4 was built to test retatrutide as a weight-loss drug in a population that also had knee osteoarthritis, not to test it as a joint treatment on its own terms. Carrying less weight reduces the mechanical load a knee joint bears with every step, which is the plausible explanation for any pain relief, rather than a direct anti-inflammatory or cartilage effect specific to the joint. TRIUMPH-4 also reported dysesthesia, an abnormal tingling or burning sensation, in 20.9% of people on the 12 mg dose versus 0.7% on placebo, a side effect not seen at this rate in retatrutide's other trials. Eli Lilly's planned FDA filing, in the first quarter of 2027, is for weight management, not for osteoarthritis. Full trial-by-trial detail, including the other TRIUMPH trials, is on the retatrutide page.
BPC-157: the most-discussed joint peptide, with the least direct human evidence
BPC-157 has a large rat and mouse literature on tendon, ligament, muscle and gut healing, mostly from one long-running Croatian research programme. None of that is a joint-pain trial specifically; it is soft-tissue repair research. The one human report that touches joints directly is a 2021 case series describing intra-articular BPC-157 injections for knee pain, published in a complementary-medicine journal. A case series has no placebo or comparison group, so it documents that injections were given, not that they caused any improvement. The US FDA nominated BPC-157 to its compounding safety-risk list in 2023 and withdrew that nomination in April 2026, which is a procedural change, not an approval. More detail on the BPC-157 page.
AOD-9604: a rabbit knee study, unrelated to its fat-loss reputation
AOD-9604 is best known for a mouse fat-loss mechanism through the beta-3 adrenergic receptor, and it has gone through six human safety trials that found no effect on IGF-1 or carbohydrate metabolism. Separately, and with no connection to that fat-loss work, a 2015 study injected AOD-9604 directly into the knee joint of rabbits with surgically induced osteoarthritis, alone or combined with hyaluronic acid. That is animal, joint-specific evidence, which puts it ahead of GHK-Cu and roughly level with TB-500 on directness, but there is no published human trial of AOD-9604 for joint pain of any kind. See the AOD-9604 page.
TB-500: almost no data specific to the fragment sold under that name
The research-market product called TB-500 is a short, 7 amino acid fragment of thymosin beta-4, a naturally occurring 43 amino acid protein. Nearly all of the substantial published human work on thymosin beta-4, including phase 3 eye-drop trials for a corneal condition and small wound-healing studies, used the full-length protein, not the short fragment. The clearest evidence for the fragment itself is a 2026 rat study that compared BPC-157, TB-500 and the combination on surgically cut Achilles tendon healing. A tendon sits alongside a joint but is not the joint itself, and this remains rat data. Thymosin beta-4 is also on the WADA Prohibited List, which matters for anyone competing. Full comparison on the TB-500 page.
GHK-Cu: strong for skin, silent on joints
GHK-Cu is a copper-binding tripeptide with a real body of evidence, but almost none of it touches joints. The human data is 8 to 12 week cosmetic cream studies on facial and eye skin. The animal data is about wound contraction and collagen in rabbit and rat skin wounds, not cartilage or synovial tissue. No study identified for this guide tested GHK-Cu, injected or topical, in an osteoarthritis or joint-injury model of any kind. Its inclusion in blends like GLOW rests on its general collagen-support mechanism, not on joint-specific research. Full detail on the GHK-Cu (injectable) page.
Reading the ranking honestly
Ranking by evidence strength alone puts retatrutide first here, because a 445-person phase 3 human trial outranks any amount of rat and rabbit data by the ordering this site uses. That should not be read as "retatrutide is the joint-pain peptide of choice." It is not marketed, studied or approved as one; the knee benefit reported in TRIUMPH-4 sits inside a much larger weight-management trial and most plausibly reflects reduced load on the joint from weight loss rather than a direct effect on cartilage or inflammation. BPC-157, AOD-9604 and TB-500 have data that at least tries to test a joint directly, just in animals rather than people. GHK-Cu has no joint-specific data at all.
Safety notes
Retatrutide's most commonly reported effects across its trials are gastrointestinal, and TRIUMPH-4 specifically flagged the dysesthesia rate above; full safety data awaits its complete phase 3 publications. BPC-157's rat literature generally reports it as well tolerated at studied doses, which says nothing about human safety, dosing or the actual contents of a research-market vial. AOD-9604's six human safety trials found no serious adverse events and no IGF-1 or glucose effects, the most reassuring human safety record of any compound on this page, even without joint-specific human efficacy data. TB-500 and GHK-Cu have no controlled human safety data for injection. See side effect management for what to monitor.
Status in the Philippines
Retatrutide is not approved anywhere and is not registered with FDA Philippines; the NBI and FDA Philippines have acted against unregistered GLP-1 sales in 2026. BPC-157, AOD-9604, TB-500 and GHK-Cu are likewise not registered with FDA Philippines as medicines and are sold locally only through research-chemical suppliers. None is a scheduled controlled substance under RA 9165, though AOD-9604 and TB-500 are both prohibited in sport by WADA. Persistent joint pain is worth evaluating with a licensed Philippine physician, since imaging and bloodwork can identify a treatable cause that no peptide here has been shown to address.
